<DOC>
	<DOCNO>NCT00459212</DOCNO>
	<brief_summary>This phase I trial study side effect best dose GTI-2040 treating patient relapse , refractory , high-risk acute leukemia , high-grade myelodysplastic syndrome , refractory blastic phase chronic myelogenous leukemia . Drugs use chemotherapy , GTI-2040 , work different way stop growth cancer abnormal cell , either kill cell stop dividing .</brief_summary>
	<brief_title>GTI-2040 Treating Patients With Relapsed , Refractory , High-Risk Acute Leukemia , High-Grade Myelodysplastic Syndromes , Refractory Blastic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose GTI-2040 patient relapse , refractory , high-risk acute leukemia , high-grade myelodysplastic syndrome , refractory blastic phase chronic myelogenous leukemia . II . Assess toxicity efficacy drug patient . III . Assess plasma intracellular pharmacokinetics drug patient . OUTLINE : This multicenter , dose-escalation study . Patients receive GTI-2040 IV continuously day 1-4 15-18 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos GTI-2040 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Blood sample collect day 1 , 4 , 15 , 19 course 1 pharmacokinetic study . Samples analyze proteomic assay , dCTP pool measurement , real-time polymerase chain reaction mRNA RRM2 , RRM1 , p53R2 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<criteria>Diagnosis 1 follow : Acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) refractory primary standard induction therapy Relapsed refractory acute leukemia Chronic myelogenous leukemia ( CML ) blast crisis diagnosis OR fail prior aggressive induction chemotherapy Diagnosis 1 follow : Acute leukemia secondary preexisting hematologic condition prior chemotherapy diagnosis OR fail prior aggressive induction chemotherapy Advanced myelodysplastic syndrome ( intermediate1 great ) De novo acute leukemia ( myeloid nonmyeloid ) Not candidate aggressive standard induction chemotherapy De novo AML ALL ( patient &gt; 60 year age ) No suspect proven active CNS leukemia ECOG performance status ( PS ) 02 OR Karnofsky PS 50100 % Life expectancy &gt; = 8 week Bilirubin = &lt; 1.5 mg/dL AST ALT &lt; 3 time upper limit normal ( ULN ) Creatinine = &lt; 1.5 time ULN No HIV positivity Fertile patient must use effective contraception No history allergic reaction attribute phosphorothiolated oligonucleotides No uncontrolled intercurrent illness include , limited , follow : Ongoing , active , poorly control infection Symptomatic congestive heart failure Unstable angina pectoris No uncontrolled intercurrent illness include , limited , follow : Cardiac arrhythmia Poorly control pulmonary disease Psychiatric illness social situation would preclude study compliance Recovered prior therapies Prior autologous allogeneic stem cell transplantation allow ( No active graftvshost disease &gt; grade 2 ) At least 2 week since prior concurrent cytotoxic chemotherapy At least 2 week since prior concurrent biologic therapy At least 2 week since prior investigational agent No concurrent anticancer therapy , include radiotherapy hormonal therapy Concurrent imatinib mesylate CML allow Not pregnant nursing Negative pregancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>